Bionano Genomics Inc to Report a Quarterly Loss of $3.02 per Share in Q1 2025

Summary

Bionano Genomics Inc is expected to report a loss of $3.02 per share for the quarter ending March 31, 2025, with quarterly revenue declining by 28.9% to $6.233 million. The company’s guidance suggests revenue between $6.2 million and $6.3 million. Analysts have an average rating of ‘hold’ for the stock, with a 12-month median target price of $7.00, higher than the last closing price of $3.84. Previous quarterly results have shown mixed outcomes, with some instances of missing earnings expectations and a few exceeding them. Reuters

Impact Analysis

1. Business Overview Analysis